The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2008 by McGill University Health Center.
Recruitment status was: Recruiting
Recruitment status was: Recruiting
Sponsor:
McGill University Health Center
Information provided by:
McGill University Health Center
ClinicalTrials.gov Identifier:
NCT00523653
First received: August 29, 2007
Last updated: March 17, 2008
Last verified: March 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Dilated cardiomyopathy (DCM) affects about 200,000 Canadians. Eighty percent of these cases are of unclear cause, often occuring in families. We believe that mutations in specific already-identified genes contribute to DCM in Quebec and that certain mutations may account for a significant proportion of cases due to the well-documented "founder effect". Two hundred patients with DCM followed in our Heart Function Clinic will be approached for one blood sample at their routine clinic visit to test this hypothesis. The samples will be tested in the Laboratory of Cardiovascular Genetics at the Royal Victoria Hospital.
| Condition | Intervention |
|---|---|
|
Dilated Cardiomyopathy (DCM) |
Other: blood test |
| Study Type: | Observational |
| Study Design: | Observational Model: Family-Based Time Perspective: Prospective |
Resource links provided by NLM:
Genetics Home Reference related topics:
X-linked dilated cardiomyopathy
familial dilated cardiomyopathy
MedlinePlus related topics:
Cardiomyopathy
U.S. FDA Resources
Further study details as provided by McGill University Health Center:
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Patients with Dilated cardiomyopathy followed at the Heart Function Clinic and their families
Criteria
Inclusion Criteria:
- Followed at MUHC Heart Function Centre
- Documented EF of less than or equal to 35% and an enlarged heart with a left ventricular end-diastolic size of greater than 6 cm.
- Patient's written consent
Exclusion Criteria:
- Patients with a known underlying condition that results in a weakened and enlarged heart
- Patients unable to read and understand the consent form
- Patients who do not wish to participate
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00523653
Please refer to this study by its ClinicalTrials.gov identifier: NCT00523653
Contacts
| Contact: Nadia S Giannetti, MD | (514)934 1934 ext 32850 | nadia.giannetti@much.mcgill.ca |
Locations
| Canada, Quebec | |
| Royal Victoria Hospital | Recruiting |
| Montreal, Quebec, Canada, H3A 1A1 | |
| Contact: Nadia Giannetti, MD nadia.giannetti@muhc.mcgill.ca | |
Sponsors and Collaborators
McGill University Health Center
Investigators
| Principal Investigator: | Nadia S Giannetti, MD | McGill University Hospital Centre |
| Principal Investigator: | Jamie Engert, PhD | McGill University Health Center |
More Information
| Responsible Party: | Dr Nadia Giannetti, McGill University Health Center |
| ClinicalTrials.gov Identifier: | NCT00523653 History of Changes |
| Other Study ID Numbers: |
BMB 07-004 |
| Study First Received: | August 29, 2007 |
| Last Updated: | March 17, 2008 |
Additional relevant MeSH terms:
|
Cardiomyopathies Cardiomyopathy, Dilated Heart Diseases Cardiovascular Diseases Cardiomegaly |
ClinicalTrials.gov processed this record on May 25, 2017